Home Newsfeeds Evercore ISI Group Maintains Outperform on Conagra Brands, Raises Price Target to $42

Evercore ISI Group Maintains Outperform on Conagra Brands, Raises Price Target to $42

Evercore ISI Group analyst David Palmer maintains Conagra Brands (NYSE:CAG) with a Outperform and raises the price target from $40 to $42.

byBenzinga Newsdesk

December 29, 2022

1 minute read

Evercore ISI Group analyst David Palmer maintains Conagra Brands (NYSE:CAG) with a Outperform and raises the price target from $40 to $42.

Is AI Ready For The Kitchen? Instacart’s AI Recipes Go Viral For All The Wrong Reasons

By Ananya Gairola

January 29, 9:29 PM

Instacart has introduced artificial intelligence in its recipe generation, leading to unusual and sometimes unappetizing results, as evidenced by peculiar AI-generated images and texts on their website.

ICRT

HC Wainwright & Co. Maintains Buy on Kala Pharmaceuticals, Raises Price Target to $20

By Benzinga Newsdesk

March 6, 7:19 AM

HC Wainwright & Co. analyst Yi Chen maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Buy and raises the price target from $12 to $20.

KALA

Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed

By Vandana Singh

June 14, 1:52 PM

Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health until the administration delivers a plan to lower prescription drug prices.

BIIB

Meta Platforms Rolling Out Ad-Free Subscription in EU Is A Revenue-Neutral Strategy: Citi

By Anusuya Lahiri

October 31, 2:45 PM

Citi analyst Ronald Josey reiterated a Buy rating on top pick Meta Platforms, Inc (NASDAQ: META) with a

Evercore ISI Group Maintains Outperform on Conagra Brands, Raises Price Target to $42

Related Posts

Is AI Ready For The Kitchen? Instacart’s AI Recipes Go Viral For All The Wrong Reasons

HC Wainwright & Co. Maintains Buy on Kala Pharmaceuticals, Raises Price Target to $20

Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed

Meta Platforms Rolling Out Ad-Free Subscription in EU Is A Revenue-Neutral Strategy: Citi